ClexBio is a biotech company creating breakthrough solutions for tissue engineering and single-cell techniques by combining advanced microfluidics with our proprietary hydrogel technology CLEX.
The CLEX technology allows hydrogel formation with, both, precise control and exceptional biocompatibility. This enables us to use microfluidic devices to form hydrogel microstructures containing delicate biological cargo such as living cells.
The CLEX technology is the results of several years of research at NTNU, Harvard University, and EPFL. The science behind CLEX has been published in internationally recognized scientific journals.
A. G. Håti et al, Versatile, cell and chip friendly method to gel alginate in microfluidic devices. Lab Chip (2016), 10.1039/C6LC00769D
A. G. Håti at al, Microarrays for the study of compartmentalized microorganisms in alginate microbeads and (W/O/W) double emulsions. RSC Adv. (2016), 10.1039/C6RA23945E
D. C. Bassett et al, Competitive ligand exchange of crosslinking ions for ionotropic hydrogel formation. J. Mater. Chem. B. (2016) 10.1039/C6TB01812B
K. Yamamoto et al, Local Structure of Ca2+ Alginate Hydrogels Gelled via Competitive Ligand Exchange and Measured by Small Angle X-ray Scattering. Gels (2019), 10.3390/gels5010003
We are a dedicated, globally minded team ready with experience from leading universities and biotech companies in Europe and the US. We are supported by a strong network of A-level entrepreneurs and innovators.
Armend co-invented the CLEX technology during his PhD & PostDoc in biophysics at NTNU, Harvard University, and EPFL. His research expertise is complemented by commercial experience from his previous position as Director for Product & Technology at Aker BioMarine.
Manuel holds a PhD in biomaterials science and tissue engineering from UiO. He also worked on national and international industry-driven research projects within nanomedicine as a Research Scientist at SINTEF and has experience in commercial product development.
Mia holds a PhD in vascular tissue engineering from the University of Oslo. During her PhD she earned a scholarship from The Fulbright Program for a research stay at Yale University on top of research stays and exchanges at the Wake Forest Institute for Regenerative Medicine, the Università degli Studi di Milano and the University of California, Berkeley.
Tia holds a PhD in Biomedicine from the University of Stavanger building on top of her MSc in Biological Chemistry. Tia has worked extensively with mammalian cell culture in conventional 2D systems, spheroids, 3D, and microfluidics. She has worked in FDA-regulated industries, with GMP experience from the Belfer Gene Therapy Core Facility at Weill Cornell Medicine and medical device R&D at Zimmer Biomet.
Martin holds an MSc in Engineering Nanoscience from Lund University. Throughout his studies, he has gained broad interdisciplinary experience in an international arena. Amongst other things, he has worked with microfluidics, organ-on-a-chip, and 3D cell culture at Lund University, Material Science at Uppsala University and Nanyang Technological University, and environmental science at Nagasaki University.
Anette holds an MSc in Molecular Medicine from NTNU and a BSc in Biomedical Science, University of the Sunshine Coast. On top of her education, she has industry experience with stem cell technology and molecular biology from her position as Assistant Scientist at Ncardia in the Netherlands, where she worked on client projects and internal research.
Cinzia is based at the University of Birmingham where she develops novel biofabrication techniques building on CLEX under supervision of the technolgy's Co-Inventor David Bassett. She holds an MRes in Biofabrication and Bioprinting from Newcastle University and a BSc in Chemistry from Swansea University. Whe focussed on regenerative medicine and has a particular passion for bioinks and bioprinting.
Andreas is an enthusiastic startup supporter and an expert in commercializing products within biotech and pharma. Currently, he is a Director of Global Pharma Strategy at Novartis and previously worked several years for McKinsey's pharma & biotech practice in Europe, China and the US. He holds an MBA from INSEAD and is a licensed lawyer.
Ramzi is a pharma pro with years of experience in sales, marketing, and market access. He co-founded the health-tech company Symmetryk and holds a senior position at Novartis and previously Roche. He holds an MSc from Stanford University and an MBA from INSEAD, where he teaches as an adjunct professor.
David is an ardent researcher at the interface of material science & biology. He co-invented CLEX together with Armend at NTNU. Currently, he works and teaches as a lecturer in Healthcare Technologies at the University of Birmingham. He holds a PhD in Biomedical Material Science from McGill University.
Lotte is a nanotechnology enthusiast with a passion for biotech. She directs Aker Biomarine's product and technology development, is a board member of The Life Science Cluster, and has been named among Norway's top 50 women in tech. She holds an MSc in nanotechnology from NTNU, spent 7 years with the Boston Consulting Group.
Anders is an experienced investment and business development professional with extensive experience in C-level positions from the health care and biotech industry. He is the Investment Director at Radforsk, chairman of Vaccibody, and has been heavily involved in the development of several biotech companies.
Vegard’s passion is helping founders identify and solve large problems and design business models for scalability. He leads the international expansion at Antler. Previously, he spent six years in McKinsey where he led teams of data scientists and consultants to solve complex problems in energy and infrastructure. Vegard holds a MSc. in Engineering from NTNU.
We are constantly looking for exceptional talent and enthusiastic investors that want to be part of our mission. Please reach out to learn more about ClexBio.
